enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. New colorectal cancer blood test approved by FDA: What to know

   www.aol.com/colorectal-cancer-blood-test...

   On July 29, 2024, the Food and Drug Administration (FDA) approved a blood test that can help with primary colorectal cancer screening. The test is Guardant Health’s Shield blood test, and the ...

3. FDA approves new blood test to screen for colon cancer

   www.aol.com/news/fda-approves-blood-test-screen...

   Updated July 29, 2024 at 9:28 AM. The Food and Drug Administration on Monday approved Guardant Health’s blood test, called Shield, to screen for colon cancer. The test isn't meant to replace ...

4. Blood test for colon cancer screening is approved by US ...

   www.aol.com/lifestyle/blood-test-colon-cancer...

   U.S. health regulators on Monday approved a first-of-its-kind blood test for colon cancer, offering a new way of screening for a leading cause of cancer deaths. Test manufacturer Guardant said the ...

5. M2-PK Test - Wikipedia

   en.wikipedia.org/wiki/M2-PK_Test

   M2-PK Test. The M2-PK Test is a non-invasive screening method for the early detection of colorectal cancers and polyps which are known to be the precursors of colorectal cancer. The M2-PK Test which is used for stool analysis is available either as fully quantitative ELISA Test or as a rapid test that can be performed by any general ...

6. Exact Sciences Corp. - Wikipedia

   en.wikipedia.org/wiki/Exact_Sciences_Corp.

   Exact Sciences Corp. is a molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown ...

7. Oncotype DX Colon Cancer Assay - Wikipedia

   en.wikipedia.org/wiki/Oncotype_DX_Colon_Cancer_Assay

   Oncotype DX Colon Cancer Assay. The Oncotype DX Colon Cancer Assay, developed by Genomic Health, is a genomic test that has been clinically available for patients with newly diagnosed stage II colon cancer, since January 2010. The test is a validated diagnostic assay based on an individual patient’s colon tumor expression of 12 genes, which ...